Just like the scenario played out when the COVID-19 pandemic became a global concern early last year, all tradable financial products are going to feel the impact, with Bitcoin being one of them.
Moderna’s top-executives have assured that the vaccine would be effective to a certain degree on the new mutations. However, they are willing to see more results under different conditions. Moderna has received a positive review from field experts as well!
Engaging an app with a wide reach like Uber to the initiative could help counter the negative impact of the misinformation.
On Monday, Moderna presented the latest report of its trials on a wide scale with a 94% efficacy rate as it awaits an FDA nod in the coming weeks soon to begin its vaccine rollout.
Besides the European Commission that just inked a deal with Moderna, the US ranks as one that has shown the highest commitment to both the vaccine development and its acquisition upon approval.
The Moderna vaccine trial involved about 30,000 participants and the interim analysis for the vaccine was based on 95 infections among the trial participants
Massachusetts-Based biotechnology company Moderna Inc (NASDAQ: MRNA), one of the top pharmaceutical companies in search of a COVID-19 vaccine, has released its Q3 financial earnings while confirming its preparations to meet up with the expected surge in demand for its vaccine once approved.
The Dow Jones dipped by 130 points as tech stocks plummeted during the Thursday’s volatile trading session. Pharmaceutical stocks are doing better these days.
Moderna COVID-19 vaccine candidate dubbed mRNA-1273 has entered its late-stage trials. The company noted that as of Wednesday, September 16, 2020, about 25,296 participants have been enrolled.
Moderna inked a $1.525 billion deal with the U.S. government for the supply of 100 million doses of its promising mRNA-1273 vaccine. MRNA stock is up in the pre-market.
Moderna said that it’s on track to finish enrollment for a phase 3 study of its vaccine by the end of September. The company reported a fivefold increase in its Q2 revenue to $66.4 million.
Moderna has got nearly $1 billion in support from the U.S. government so far to support the development of the COVID-19 vaccine. The biotech firm is conducting its last-stage trials. MRNA stock is up.
Moderna said its experimental coronavirus vaccine demonstrated immune responses in some of the healthy volunteers who were vaccinated in a clinical study. MRNA stock is up.
Moderna (MRNA) stock has more than tripled in value since the beginning of the year but has lost 6.80% on Tuesday. Moderna CEO Stephane Bancel said no single manufacturer can make enough coronavirus vaccine doses for the planet.
It has become known that the supply of Moderna’s coronavirus vaccine will be limited and the U.S. government will help to choose who will be the first to get it. Meanwhile, today Moderna (MRNA) stock is around 10% up.